文献速递甲状腺疾病

晚期非甲状腺癌患者酪氨酸激酶抑制剂治疗期间新发甲状腺功能减退的危险因素

Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
PubMed 文献 · Thyroid · 2018-01-01

该回顾性队列研究纳入2000至2017年接受酪氨酸激酶抑制剂(TKI)治疗的538例晚期非甲状腺癌且初始甲状腺功能正常患者,评估新发甲状腺功能减退的危险因素。结果显示亚临床甲状腺功能减退发生率为13.2%,临床甲状腺功能减退为26.8%;作者推荐监测甲状腺功能,尤其关注女性及新用TKI后前6个月。

要点

  • TKI治疗期间甲状腺功能异常发生率达40%,其中临床甲状腺功能减退占26.8%。
  • 甲状腺功能减退风险在TKI治疗前6个月内最高,推荐监测甲状腺功能。

核心结论

  • 在接受TKI治疗的初始甲状腺功能正常的晚期非甲状腺癌患者中,甲状腺功能异常发生率为40%,女性及TKI治疗前6个月内风险较高。

研究设计与样本

  • 回顾性队列研究,纳入2000至2017年接受TKI治疗的538例晚期非甲状腺癌且初始甲状腺功能正常的成人患者。

主要发现

  • 538例患者中亚临床甲状腺功能减退71例(13.2%),临床甲状腺功能减退144例(26.8%),中位累积TKI暴露时间为196天(IQR 63.5-518.5天)。
  • 甲状腺功能减退风险在TKI治疗前6个月内最高。
  • 仅使用一种TKI的患者中,与甲状腺功能异常并发的中位TKI暴露时间为85天(IQR 38-293.5天),既往使用过其他TKI的患者为74天(IQR 38-133.3天),两者差异无统计学意义(P=0.41)。
  • 更大的累积TKI暴露量和更多的TKI种类数与甲状腺功能异常无关。

关键数值与推荐

  • 亚临床甲状腺功能减退定义:促甲状腺激素(TSH)5-10 mIU/L,或TSH更高但游离甲状腺素正常。
  • 临床甲状腺功能减退定义:TSH>10 mIU/L、游离甲状腺素降低,或需要甲状腺激素替代治疗。

临床怎么用

  • 作者推荐对接受TKI治疗的患者监测甲状腺功能,尤其关注女性患者及新用TKI后的前6个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid dysfunction during tyrosine kinase inhibitor (TKI) cancer treatment is common, but predisposing risk factors have not been determined. Recommendations for monitoring patients treated with one or multiple TKI and in conjunction with other relevant cancer therapies could be improved. The study objective was to assess the risk factors for new thyroid dysfunction in TKI-treated previously euthyroid cancer patients. METHODS: A retrospective cohort study of patients with advanced nonthyroidal cancer treated with TKI from 2000 to 2017, having available thyroid function tests showing initial euthyroid status, excluding patients with preexisting thyroid disease or lack of follow-up thyroid function tests. During TKI treatment, patients were classified as euthyroid (thyrotropin [TSH] normal), subclinical hypothyroidism (TSH 5-10 mIU/L, or higher TSH if free thyroxine normal), or overt hypothyroidism (TSH >10 mIU/L, low free thyroxine, or requiring thyroid hormone replacement). The timing of thyroid dysfunction and TKI used were assessed. Risk factors for incident hypothyroidism were evaluated using multivariate models. RESULTS: In 538 adult patients included, subclinical hypothyroidism occurred in 71 (13.2%) and overt hypothyroidism occurred in 144 (26.8%) patients with TKI therapy, following a median cumulative TKI exposure of 196 days (interquartile range [IQR] 63.5-518.5 days). The odds of hypothyroidism were greatest during the first six months on a TKI. Median exposure time on the TKI concurrent with thyroid dysfunction in patients treated with only one TKI was 85 days (IQR 38-293.5 days) and was similar to the 74 days (IQR 38-133.3 days) in patients treated previously with other TKI (p = 0.41). Patients who developed hypothyroidism compared to those who remained euthyroid had greater odds of being female (odds ratio = 1.99 [confidence interval 1.35-2.93], p < 0.01), but greater cumulative TKI exposure and greater number of TKI received were not associated with thyroid dysfunction. CONCLUSIONS: Thyroid dysfunction occurred in 40% of euthyroid patients. Monitoring thyroid function in TKI-treated patients is recommended, with particular attention to female patients and within the first six months of exposure to a new TKI.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lechner MG, Vyas CM, Hamnvik OR, et al. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. Thyroid. 2018. PMID: 29652599. doi:10.1089/thy.2017.0579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。